🕒 Last update: loading…

Stock Taysha Gene Therapies, Inc. TSHA

Taysha Gene Therapies, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2020 → 2021: -56.10%

Price change 2021 → 2022: -80.60%

Price change 2022 → 2023: -21.68%

Price change 2023 → 2024: -2.26%

Price change 2024 → 2025: 217.92%

Price change 2025 → 2026: -13.82%

Price change 2026 (year to date): -9.71%

Financial growth

Revenue CAGR (7 years): N/A

Earnings CAGR (7 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.07

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -11.02

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 32.09% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Taysha Gene Therapies, Inc.–0.07–🔒
Clariane SE611.52.16+12.4 %–
BioGaia AB (publ)32.70.01+13.3 %–
Nutex Health, Inc.6.91.07+54.6 %–
Gerresheimer AG31.71.48+5.6 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Taysha Gene Therapies, Inc. over the latest fiscal years.

Revenue
9.8 m USD
fiscal year 2025
Net income
-109 m USD
fiscal year 2025
Net margin
-1,115.3 %
fiscal year 2025
Market cap
1.3 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20222.5 m-166 m-6,635.2 %n/a
202315.5 m-112 m-722.1 %+517.5 %
20248.3 m-89.3 m-1,071.6 %-46.1 %
20259.8 m-109 m-1,115.3 %+17.3 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Taysha Gene Therapies, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
6.65
safe zone (above 2.99)
Piotroski Score
3 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
2.37 x
moderate debt
Fiscal year20212022202320242025
Cash and investments149 m87.9 m144 m139 m320 m
Total Debt63.1 m59.9 m61.1 m63.2 m18.2 m
Net Debt-86.0 m-28.0 m-82.8 m-75.9 m-302 m
Equity95.4 m949,00074.9 m71.5 m247 m
Total assets214 m126 m173 m160 m343 m
Operating cash flow-117 m-88.4 m-73.0 m-81.2 m-93.1 m
Investments (capex)15.3 m24.9 m3.9 m374,000738,000
Free cash-flow-139 m-113 m-80.4 m-81.6 m-93.8 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-8.77 x
Price / book value4.29 x
Return on Equity (ROE)-51.9 %
Return on Invested Capital (ROIC)-39.0 %
Net margin-2,844.6 %
Debt / equity0.15 x
Current ratio18.56 x
Interest coverage-5,193.77 x
Free cash-flow yield-11.8 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

Taysha Gene Therapies, Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Taysha Gene Therapies, Inc.1.3 bnn/a-1,115.3 %
Neurogene Inc. NGNE378 mn/a0.0 %
4D Molecular Therapeutics, Inc. FDMT676 mn/a-164.4 %
Voyager Therapeutics, Inc. VYGR108 mn/a-296.5 %
Abeona Therapeutics Inc. ABEO138 mn/a1,223.1 %
Passage Bio, Inc. PASG13.7 mn/a0.0 %
REGENXBIO Inc. RGNX505 mn/a-113.8 %
Rocket Pharmaceuticals, Inc. RCKT257 mn/a0.0 %
Sarepta Therapeutics, Inc. SRPT1.7 bnn/a-32.5 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Taysha Gene Therapies, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
18 analysts

Breakdown of ratings

strong buy 0buy 15hold 3sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 6 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Taysha Gene Therapies, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
12/11/2026-0.10-0.13n/a
11/08/2026-0.13-0.11n/a
06/05/2026-0.12-0.10n/a
19/03/2026-0.08-0.11n/a
04/11/2025-0.09-0.09n/a
12/08/2025-0.09-0.07n/a

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Taysha Gene Therapies, Inc.

Free float
84.5 %
share of freely traded shares
Large funds tracked
20
hold the stock as of 2026Q2

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
State Street22.8 m156 m0.0 %+103.8 %2026Q2
Goldman Sachs22.7 m155 m0.0 %+1.5 %2026Q2
BlackRock20.7 m141 m0.0 %+12.7 %2026Q2
Morgan Stanley16.5 m112 m0.0 %-8.2 %2026Q2
Fidelity13.3 m90.8 m0.0 %-6.9 %2026Q2
Vanguard Group13.3 m73.0 m0.0 %+3.3 %2025Q4
Geode Capital Management6.6 m44.7 m0.0 %+18.6 %2026Q2
D. E. Shaw & Co4.4 m30.0 m0.0 %-0.6 %2026Q2

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 24/09/2020
ISIN code
US8776191061
Workforce
73
full-time employees
Chief executive
Sean P. Nolan

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Taysha Gene Therapies, Inc.

What is the Taysha Gene Therapies, Inc. share price?

Latest recorded price: 4.10 USD on 13/11/2026, for a market cap of 1.3 bn USD.

What is the revenue of Taysha Gene Therapies, Inc.?

9.8 m USD for fiscal year 2025, with net income of -109 m USD (net margin -1,115.3 %).

What do analysts say about Taysha Gene Therapies, Inc.?

Out of 18 analysts: 15 buy or strong buy, 3 hold, 0 sell or strong sell.

Is Taysha Gene Therapies, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US8776191061).

How many employees does Taysha Gene Therapies, Inc. have?

73 full-time employees according to the latest published profile.

Who runs Taysha Gene Therapies, Inc.?

Sean P. Nolan is the company's chief executive.

Which large funds own Taysha Gene Therapies, Inc.?

As of 2026Q2, among the large funds tracked: State Street, Goldman Sachs, BlackRock, Morgan Stanley, Fidelity.

07

Similar stocks